Particle.news
Download on the App Store

Kimberly-Clark to Acquire Tylenol Owner Kenvue in $48.7 Billion Cash-and-Stock Deal

The merger awaits shareholder and regulatory approval before an expected close in the second half of 2026.

Overview

  • Kenvue shareholders will receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per share, valuing Kenvue at about $21.01 based on Friday’s close.
  • Post-close ownership is set at roughly 54% for Kimberly-Clark shareholders and 46% for Kenvue holders, with Mike Hsu to lead the combined company and three Kenvue directors joining the board.
  • The combined business is projected to generate about $32 billion in 2025 revenue across 10 billion-dollar brands, with $1.9–$2.1 billion in cost savings targeted within three years of closing.
  • Markets reacted swiftly to the announcement, with Kenvue up about 18%–20% and Kimberly-Clark down roughly 12%–16% in early trading.
  • The transaction follows Kenvue’s post-IPO underperformance and leadership change and proceeds under legal and political scrutiny tied to disputed Tylenol–autism claims and a new Texas lawsuit.